Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search



You are here People

Lorraine O'Driscoll
Professor, Pharmacy

RESEARCH INTERESTS

Lorraine holds a BSc (Hons) in Pharmacology, MSc (Res) in Clinical Pharmacology, and PhD in Biotechnology. Following her PhD, Lorraine worked on biotechnology/biomedical research studies for US and EU industry (includuing Berlex/Bayer HealthCare Pharmaceuticals; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader, NICB and Lecturer in School of Biotechnology, DCU. Lorraine’s research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer.

She has been a Principal Investigator and lead on cancer clinical trials for the All Ireland Cooperative Oncology Research Group since 2006. She is TCD’s Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported National Cancer Research Institute, Breast-PREDICT; and Lead Principal Investigator and Chair, EU FP7 EuropeanNetwork Cooperation in Science and Technology focussed on Exosomes & Microvesicles in health & Disease which brings together researchers from 27 European countries, 2 US universities, an Australian Institute and 7 industry partners. Lorraine’s background, drawing on expertise developed in industry and in academia, provides her with expertise in many areas of pharmaceutical sciences, pharmacology and biotechnology including extensive pre-clinical in vitro and in vivo studies and clinical trial development.

FINANCIAL SUPPORT

EU H2020 & FP7; Science Foundation Ireland (SFI); Health Research Board (HRB); Enterprise Ireland (E.I.); Danish Strategic Research Council/EU; Marie Keating Foundation; Irish Cancer Society (ICS); Higher Education Authority PRTLI; AdnaGen AG; Arla Health Foods; Pfizer; Bayer.

Biography

Lorraine O'Driscoll (BSc(Hons, Pharm), MSc(Res, Clin Pharm), MA(Ed), PhD(Biotech), FTCD)

Lorraine holds a BSc(Hons), pharmacology; MSc(Res), clinical pharmacology; MA, education; PhD, biotechnology. In 2012, she was elected to Fellowship in TCD. Following her PhD, Lorraine undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU. Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer. She has been a P.I. on 5 cancer clinical trials with ICORG. She is TCD's Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and P.I. and Chair, H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from 27 European countries, 3 US universities, Australia and 7 industry partners. In 2017, she was awarded approx. €4,000,000 as Director of a H2020 ITN aimed at training 15 PhD students in TRAIN-EV i.e. training in extracellular vesicles: for benefit in health and disease. She has developed tailored courses for academia (e.g. FEBS), semi-state bodies (e.g. IDA) and industry. Her graduates and mentees are now employed at NIH; Pfizer; Amgen; Leo; Roche; AstraZeneca; ICON plc; 2 are entrepreneurs/company CEOs; 2 are Managers of Research Centres; others hold lecturing and research posts in academia.

Publications and Further Research Outputs

Peer-Reviewed Publications

Thery C,...O'Driscoll L.. (alphabetical order).., Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines, J. Extracell. Vesicles, 2019 Journal Article, 2019 URL

Lowry MC, O'Driscoll L, Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?, Drug Discovery Today, 23, (6), 2018, p1267 - 1273 Journal Article, 2018 URL DOI

Conlon NT, Lowry MC, Breslin S, O'Driscoll L, Eustace AJ, Crown J, O'Donovan N, Collins DM., Src inhibition overcomes neratinib-resistance in HER2-positive breast cancer., Expt. Mol. Therapeutics., Amer. Assoc. for Cancer Res. (AACR), Chicago, US, 78, (13), 2018, pp1834 - 1835 Published Abstract, 2018

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J., Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL., BMC Cancer, 18, (1), 2018 Journal Article, 2018 URL DOI

Lowry MC, Breslin S, O'Driscoll L., Investigating the roles of macrophage colony-stimulating factor (CSF1) and carbonic anhydrase 9 (CAIX) in neratinib-resistant HER2+ breast cancer cell lines and extracellular vesicles., J. Extracell. Vesicles., 7, (1), 2018, pp23 - 23 Published Abstract, 2018 URL DOI

O'Neill S, Larsen MB, Gregersen S, Hermansen K, O'Driscoll L., miR-758-3p: a blood-based biomarker that's influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome., Oncotarget, 9, (10), 2018, p9379 - 9390 Journal Article, 2018 URL TARA - Full Text DOI

McNamee N, O'Driscoll L, Extracellular vesicles and anti-cancer drug resistance, BBA Cancer, 1870, (2), 2018, p123 - 136 Journal Article, 2018 DOI URL

EV-TRACK Consortium,.. O'Driscoll L. , EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research., Nature Methods, 14, (3), 2017, p228 - 232 Journal Article, 2017 URL DOI

Breslin S, Lowry M, O'Driscoll L, Neratinib-resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4, British Journal of Cancer, 116, (5), 2017, p620 - 625 Journal Article, 2017 DOI URL

O'Driscoll L, Stoorvogel W, Thery C, Buzas E, Nazarenko I, Siljander P, Yanez-Mo M, Fais S, Giebel B, Yliperttula M, European Network on Microvesicles and Exosomes in Health and Disease, European Journal of Pharmaceutical Sciences, 98, 2017, p1 - 3 Journal Article, 2017 URL DOI

Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome in, editor(s)Rani S , Meth. Mol. Biol., New York, Springer, 2017, pp141 - 149, [O'Neill S, O'Driscoll L] Book Chapter, 2017 URL DOI TARA - Full Text

Martinez VG, Crown J, Porter RK, O'Driscoll L., Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer, International Journal of Cancer, 140, (12), 2017, p2771 - 2784 Journal Article, 2017 URL DOI

MicroRNA Profiling of Exosomes in, editor(s)Rani S , Methods in Molecular Biology, New York, Springer, 2017, pp37 - 46, [Daly M, O'Driscoll L] Book Chapter, 2017 DOI URL TARA - Full Text

Gaynor N, Guibourdenche M, Browne B, O'Driscoll L, O'Brien N, O'Donovan N, Crown J, Collins D., Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity T-ADCC in a lapatinib-resistant HER2 breast cancer cell line model., Annals Oncol., 28, (5), 2017, pp14 - 15 Published Abstract, 2017 URL

Martinez VG, O'Neill S, Salimu J, Breslin S, Clayton A, Crown J, O'Driscoll L., Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles., Oncoimmunology, 6, (12), 2017, p530 - 540 Journal Article, 2017 URL DOI

Martinez VG, O'Driscoll L, Neuromedin U drives increased expression of TGF beta 1 in HER2-positive breast cancr cells and their extracellular vesicles: a novel biomarker of response to HER-targeted drugs., Cancer Research , 76, (14), 2016, pp116 - 117 Published Abstract, 2016

O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L., Blood-based biomarkers for metabolic syndrome, Trends in Endocrinology & Metabolism, 27, (6), 2016, p363 - 374 Journal Article, 2016 TARA - Full Text DOI URL

Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, A, Sammar M, Llorente A, Nazarenko I, Oliveira C, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Bedina Zavec A, Giebel B., Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine, ASC Nano, 10, (4), 2016, p3886 - 3899 Journal Article, 2016 URL DOI

Breslin S, O'Driscoll L, The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance., Oncotarget, 7, (29), 2016, p45745 - 45756 Journal Article, 2016 DOI URL TARA - Full Text

Martinez VG, O'Driscoll L, Neuromedin U: A Multifunctional Neuropeptide with Pleiotropic Roles., Clin. Chem., 61, (3), 2015, p471 - 482 Journal Article, 2015 URL DOI TARA - Full Text

Lowry MC, Gallagher WM, O'Driscoll L, The Role of Exosomes in Breast Cancer, Clin. Chem., 61, (12), 2015, p1457 - 1465 Journal Article, 2015 URL DOI TARA - Full Text

Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, O'Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BW, Wauben M, Andaloussi SE, Théry C, Rohde E, Giebel B. , Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper., Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. , 30087, (4), 2015, p1 - 35 Journal Article, 2015 TARA - Full Text DOI URL

O'Neill S, O'Driscoll L, Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. , Obes. Rev., 16, (1), 2015, p1 - 12 Journal Article, 2015 URL DOI TARA - Full Text

Bohl M, Bjørnshave A, Rasmussen KV, Grethe Schioldan A, Amer B, Larsen MK, Dalsgaard TK, Holst JJ, Herrmann A, O'Neill S, O'Driscoll L, Afman L, Jensen E, Christensen MM, Gregersen S, Hermansen K. , Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. , Amer. J. Clin. Nutrition. , 101, (4), 2015, p870 - 878 Journal Article, 2015 URL DOI TARA - Full Text

O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L., miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity., Oncotarget, 6, (32), 2015, p32774 - 32789 Journal Article, 2015 TARA - Full Text URL DOI

Martinez VG, Rani S, Corcoran C, Crown J, O'Driscoll L., Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells., J Clin. Oncol., 33, (15), 2015, pp614 - 615 Published Abstract, 2015 URL TARA - Full Text

Lowry MC, Gallagher WM, O'Driscoll L., The role of exosomes in breast cancer., Clinical Chemistry, 61, (12), 2015, p1457 - 1465 Journal Article, 2015 DOI URL TARA - Full Text

Analysis of changes in phosphorylation of Receptor Tyrosine Kinases: antibody arrays in, editor(s)O'Driscoll L , Meth. Mol. Biol., 2015, pp15 - 23, [Rani S, O'Driscoll L] Book Chapter, 2015 DOI TARA - Full Text URL

Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O, Biological properties of extracellular vesicles and their physiological functions., J. Extracellular Vesicles, 4, 2015, p27066 - 27098 Journal Article, 2015 URL DOI TARA - Full Text

O'Driscoll L., Expanding on Exosomes and Ectosomes in Cancer, New Eng. J. Medicine, 372, (24), 2015, p2359 - 2362 Journal Article, 2015 URL DOI TARA - Full Text

Receptor tyrosine kinase targeting in multicellular spheroids. in, editor(s)O'Driscoll L , Meth. Mol. Biol., 2015, pp161 - 168, [Breslin S, O'Driscoll L] Book Chapter, 2015 TARA - Full Text DOI URL

Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors. in, editor(s)O'Driscoll L , Meth. Mol. Biol., 2015, pp169 - 180, [Corcoran C, O'Driscoll L] Book Chapter, 2015 DOI URL TARA - Full Text

Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N, Predictive biomarkers for dasatinib treatment in melanoma , Oncoscience, 1, (2), 2014, p158 - 166 Journal Article, 2014 URL DOI TARA - Full Text

Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O'Driscoll L, miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer , Mol. Cancer, 13, 2014, p71 - 79 Journal Article, 2014 TARA - Full Text DOI URL

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L, Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors., Cancer Research, 74, (14), 2014, p3821 - 3833 Journal Article, 2014 DOI URL TARA - Full Text

Corcoran C, Rani S, Prencipe M, O'Neill A, Watson W, O'Driscoll L. , miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. , J. Extracellular Vesicles. , 3, (24214), 2014, pp360 - 360 Published Abstract, 2014 URL DOI TARA - Full Text

Corcoran C, Rani S, O'Driscoll L, miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression., The Prostate, 74, (13), 2014, p1320 - 1334 Journal Article, 2014 URL TARA - Full Text DOI

O'Brien K, Corcoran C, Rani S, Crown J, Radomski M, O'Driscoll L., miR-134 transported in extracellular vesicles reduces triple-negative breast cancer aggression., J. Extracell. Vesicles., 3, (24214), 2014, pp143 - 144 Published Abstract, 2014 DOI URL TARA - Full Text

Jella KK, Rani S, O'Driscoll L, McClean B, Byrne HJ, Lyng FM. , Exosomes are involved in mediating radiation induced bystander signaling in human keratinocyte cells. , Radiat. Res. , 181, (2), 2014, p138 - 145 Journal Article, 2014 URL TARA - Full Text DOI

O'Brien K, Corcoran C, Rani S, McDonnell S, Hughes L, Radomski M, Crown J, O'Driscoll L. , The Relevance of exosomal-miRNAs in triple-negative breast cancer progression. , J. Extracell. Vesicles., 2, 2013, pp122 - 122 Published Abstract, 2013 URL TARA - Full Text DOI

Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L, Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma., Cancer Biology & Therapy, 14, (12), 2013, p1104 - 1112 Journal Article, 2013 DOI TARA - Full Text URL

Hill AF, Pegtel DM, Lambertz U, Leonardi T, O'Driscoll L, Pluchino S, Ter-Ovanesyan D, Nolte-'t Hoen EN. , ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. , J. Extracell. Vesicles., 2013, p22859- Review Article, 2013 DOI URL TARA - Full Text

Breslin S, Corcoran C, Rani S, Crown J, O'Driscoll L. , Assessment of neratinib-resistance and cross-resistance in HER2-overexpressing breast cancer cells. , J. Clin. Oncol. , 31, (15), 2013, pp11520 - 11521 Published Abstract, 2013 URL TARA - Full Text

Breslin S, O'Driscoll L, 3-Dimensional cell culture: the missing link in drug discovery., Drug Discovery Today, 18, (5-6), 2013, p240 - 249 Review Article, 2013 TARA - Full Text URL DOI

O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O'Driscoll L, Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. , Eur. J. Cancer, 49, (8), 2013, p1845 - 1859 Journal Article, 2013 URL TARA - Full Text DOI

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M. , Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis., Carcinogenesis, 34, (10), 2013, p2300 - 2308 Journal Article, 2013 DOI TARA - Full Text URL

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ , Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. , Cancer Biol Ther. , 14, (6), 2013, p537 - 545 Journal Article, 2013 URL TARA - Full Text DOI

Corcoran C, Rani S, Breslin S, Ghobrial IM, Crown J, O'Driscoll L., The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs. , J. Clin. Oncol., 31, (15), 2013, pp620 - 621 Published Abstract, 2013 TARA - Full Text URL

Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. , EGFR and HER2 inhibition in pancreatic cancer. , Invest. New Drugs, 31, (3), 2013, p558 - 566 Journal Article, 2013 TARA - Full Text URL DOI

Breslin S, O'Driscoll L., Three-dimensional cell culture: The missing link in drug discovery, Drug Discovery Today, 18, (5-6), 2013, p240 - 249 Journal Article, 2013 URL DOI TARA - Full Text

Rani S, Germano S, Madden SF, Corcoran C, Breslin S, O'Brien NA, McDermott M, Browne B, O'Donovan N, Crown J, O'Driscoll L. , Neuromedin U: A potential predictive biomarker for HER2-targeted drugs. , J. Clin. Oncol. , 30, (15), 2012, pp617 - 617 Published Abstract, 2012 URL DOI TARA - Full Text

Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L. , Generation and Characterisation of Neratinib-resistant Breast Cancer Cell Line Variants., Eur. J. Cancer, 48, 2012, pp32 - 33 Published Abstract, 2012 DOI URL TARA - Full Text

Chen X, Hermansen K, Xiao J, Bystrup SK, O`Driscoll L, Jeppesen PB. , Isosteviol has beneficial effects on palmitate-induced cell dysfunction and gene expression. , PLoS One , 7, (3), 2012, p34361 - 34369 Journal Article, 2012 TARA - Full Text DOI URL

Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L., MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis., International Journal of Cancer, 130, 2012, p1991 - 2002 Journal Article, 2012 DOI URL TARA - Full Text

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Crown J, Watson W, O'Driscoll L. , Exosomes: potential regulators and biomarkers of prostate cancer progression. , J. Extracell. Vesicles., 51, (76), 2012, pp34 - 35 Published Abstract, 2012 DOI TARA - Full Text URL

Corcoran C, Rani S, O'Neill A, Prencipe M, O'Brien A, O'Brien K, Crown J, Watson WG, O'Driscoll L. , The relevance of exosomes in prostate cancer and their potential to confer docetaxel resistance to secondary cells. , Cancer Research , 72, (8), 2012, pp794 - 795 Published Abstract, 2012 URL TARA - Full Text DOI

O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Meleady P, O'Driscoll L, Watson W, O'Connor R. , The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. , Proteomics, 12, (13), 2012, p2115 - 2126 Journal Article, 2012 URL TARA - Full Text DOI

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, Mc Dermott R, Watson W, Crown J, O'Driscoll L. , Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. , PloS One, 7, (12), 2012, pe50999-51009 Journal Article, 2012 URL TARA - Full Text DOI

Radziwon-Balicka A, Medina C, O'Driscoll L, Treumann A, Bazou D, Inkielewicz-Stepniak I, Radomski A, Jow H, Sawicki G, Radomski MW., Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. , Brit. J. Pharmacol., 167, (4), 2012, p787 - 804 Journal Article, 2012 URL TARA - Full Text DOI

O'Driscoll L, Exosomal RNA as Cancer Biomarkers, "X International Society for Extracellular Vesicles Biomarker Workshop , New York, US, Sept 2012, 2012 Oral Presentation, 2012

O'Brien K, Rani S, Wallace R, McDonnell S, Hughes L, Radomski M and O'Driscoll L. , Can exosomes influence triple negative breast cancer metastasis?, J. Extracell. Vesicles., 51, 2012, pp74 - 75 Published Abstract, 2012 DOI URL TARA - Full Text

Eustace AJ, Browne BC, McDermott M, O'Leary P, O'Driscoll L, O'Brien N, Gallagher N, Watson W, Crown J, O'Donovan N. , Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive, Eur. J. Cancer, 48, 2012, pp44 - 45 Published Abstract, 2012 DOI URL TARA - Full Text

Eustace AJ, Browne B, Madden SF, O'Driscoll L, McDermott M, O'Brien NA, Watson W, Crown J, Walsh N, O'Donovan N. , Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX. , J. Clin. Oncol. , Amer. Soc. Clin. Oncol. (ASCO), Chicago, US, June 2012, 30, (15), 2012, pp633 - 634 Published Abstract, 2012 URL TARA - Full Text

Corcoran C, Rani S, Brown B, Crown J, O'Donovan N, O'Driscoll L, Extracellular miRNAs have potential as minimally-invasive biomarkers for predicting response to HER2-targeted agents, including Trastuzumab, as used in breast cancer , Cancer Research , Amer. Assoc. for Cancer Res. (AACR), April 2011, 71, 2011, pp4938 - 4939 Published Abstract, 2011 URL DOI

O'Driscoll L, Rani S, Marker and Target for Responsiveness and Resistance to Cancer Agents, 2011, WO2013057323 Patent, 2011 URL

Corcoran C, Rani S, O'Brien K, Crown J, O'Driscoll L. , Establishing and characterising new in vitro models of docetaxel-resistance in prostate cancer. , Eur. J. Cancer, Europ. Soc. Med. Oncol., Stockholm, Sweden, Sept 2011, 47, 2011, pp489 - 490 Published Abstract, 2011 URL DOI

Germano S, O'Driscoll L., Western blotting analysis as a tool to study receptor tyrosine kinases., Methods Mol Biol. , 784, 2011, p109 - 121 Journal Article, 2011 DOI URL TARA - Full Text

O'Driscoll L. , microRNAs-key contributors to endocrinology. , BioScientifica, 25, (4), 2011, pp1- Published Abstract, 2011 TARA - Full Text URL

O'Driscoll L, O'Byrne K, LUNGMARK, 2011, US20130059742 Patent, 2011 URL

Eustace AJ, Kennedy S, Larkin A, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. , Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma. , J. Clin. Oncol., Amer. Soc. Clin. Oncol., Chicago, US, 2011, 29, (15), 2011, pp8578 - 8578 Published Abstract, 2011 TARA - Full Text URL

Rani S, O'Driscoll L. , Function of beta cell and extracellular RNAs as potential biomarker. Defining beta cell function and elucidating extracellular RNAs as potential biomarker. , Academic Press, 2011 Book, 2011

Rani S, O'Brien K, McDonnell S, Hughes L, Friel AM, Radomski MW, Crown J, O'Driscoll L. , Triple-negative Breast Cancer Cells May Transfer Phenotypic Characteristics via Exosomes. , Eur. J Cancer , Europ. Soc. Med. Oncol., Stockholm, Sweden, Sept 2011, 47, 2011, pp143 - 144 Published Abstract, 2011 URL TARA - Full Text DOI

Hennessy E, O'Driscoll L., MicroRNA expression analysis: techniques suitable for studies of intercellular and extracellular microRNAs., Methods Mol Biol., 784, 2011, p99 - 107 Journal Article, 2011 DOI URL TARA - Full Text

O'Driscoll L., Gene Expression Profiling: Methods and Protocols, Second Edition, Second, 2011, 1 - 211pp Book, 2011 URL

Rani S, O'Driscoll L., Reverse-transcriptase polymerase chain reaction to detect extracellular mRNAs., Methods Mol Biol. , 784, 2011, p15 - 25 Journal Article, 2011 TARA - Full Text DOI URL

O'Driscoll L, Doolan P, Clynes M., 'New assay for breast cancer comprises mRNA encoding markers, useful for diagnosing, prognosing, or predicting breast cancer.', Publ.of the Int.Appl. without Int.search REP. - World Intellectual Property Organization, WO2008132167-A2 ; WO2008132167-A3, 2011, 25 April 2008 Patent, 2011 URL

4. Rani S, Gately K, O'Byrne K, O'Driscoll L. , Circulating miRNA as minimally-invasive biomarkers for adenocarcinoma of the Lung. , J. Thoracic Oncol. , 14th World Conference on Lung Cancer. , Amsterdam, The Netherlands. , 6, (6), 2011, pp1036 - 1037 Published Abstract, 2011

Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L., Intracellular and extracellular microRNAs in breast cancer., Clin Chem. , 57, (1), 2011, p18 - 32 Journal Article, 2011 TARA - Full Text URL DOI

Sheridan H, Nestor C, O'Driscoll L, Hook I., Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of Streptocarpus dunnii., J Nat Prod., 71, (1), 2011, p82 - 85 Journal Article, 2011 URL TARA - Full Text DOI

O'Neill, AJ, Prencipe, M, Dowling, C, Fan, Y, Mulrane, L, Gallagher, WM, O'Connor, D, O'Connor, R, Devery, A, Corcoran, C, Rani, S, O'Driscoll, L, Fitzpatrick, JM, Watson, RWG, Characterisation and manipulation of docetaxel resistant prostate cancer cell lines, Molecular Cancer, 10, 2011, p126 - 135 Journal Article, 2011 TARA - Full Text DOI URL

Friel, A.M., Crown, J., O'Driscoll, L., Analysis of gene expression as relevant to cancer cells and circulating tumour cells, Methods in Molecular Biology, 784, 2011, p55-75 Journal Article, 2011 URL DOI

Rani S, O'Brien K, Kelleher FC, Corcoran C, Germano S, Radomski MW, Crown J, O'Driscoll L., Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling., Methods Mol Biol., 784, 2011, p181 - 195 Journal Article, 2011 TARA - Full Text URL DOI

O'Driscoll, L., Editorial: Preface: Gene expression profiling methods and protocols second edition, Methods in Molecular Biology, 784, 2011 Journal Article, 2011

Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L, Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis, British Journal of Cancer, 102, 2010, p1157-1162 Journal Article, 2010 TARA - Full Text DOI URL

Translating In Vitro Cell Lines result into Clinical Practice. in, editor(s)Hayat MA (ed.) , Methods of Cancer Diagnosis, Therapy, and Prognosis, Switzerland AG. , Springer Nature , 2010, pp183 - 191, [Mehta JP, O'Driscoll L, Barron N, Clynes M, Doolan P.] Book Chapter, 2010 URL

Rani S, Mehta JP, Barron N, Doolan P, Jeppesen PB, Clynes M, O'Driscoll L, Decreasing Txnip mRNA and Protein Levels in Pancreatic MIN6 Cells Reduces Reactive Oxygen Species and Restores Glucose Regulated Insulin Secretion., Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 25, (6), 2010, p667-674 Journal Article, 2010 DOI

Friel AM, Corcoran C, Crown J, O'Driscoll L., Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer., Breast Cancer Res Treat. , 123, (3), 2010, p613 - 615 Journal Article, 2010 DOI TARA - Full Text URL

Hennessy E, Clynes M, Jeppesen P, O'Driscoll L, Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells., Biochemical and Biophysical Research Communications, 396, (2), 2010, p457 - 462 Journal Article, 2010 URL TARA - Full Text DOI

Eustace AJ, Mahgoub T, Kennedy S, Crown J, Larkin A, Tryfonopoulos D, O'Driscoll L, Clynes M, O'Donovan N., Targeting SRC kinase (SRC) in melanoma cells. , J. Clin. Oncol., 28, (15), 2010, pp8584 - 8586 Published Abstract, 2010

Germano S, Rani S, Kennedy S, Clynes M, Crown J, O'Driscoll L., Clinical significance and functional relevance of MAGED-4B in breast cancer. , Annals Oncol., 21, 2010, pp69 - 69 Published Abstract, 2010

Lewis A Chodosh(ed.), Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer, Breast Cancer Research, 12, (1), 2010, 10-11 p Proceedings of a Conference, 2010 URL TARA - Full Text

Germano S, Kennedy S, Hughes L, McDonnell S, Mehta JP, Doolan P, Clynes M, O'Driscoll L, Characterisation of Neuronal Calcium Sensor-1 (NCS-1) as a novel prognostic biomarker with potential therapeutic implications for triple negative breast cancer, Ann Oncol, 20, (2), Oxford Journals; Oxford University Press, 2009, pp49 - 50 Meeting Abstract, 2009

O'Driscoll L, Mechanisms of drug sensitivity and resistance in cancer., Curr. Cancer Drug Targets, 9, (3), 2009, p250 - 251 Journal Article, 2009

Tisdall AR, Rani S, Hennessy E, Wickham S, Dowling P, Bennett K, Abdin R, Wahab RA, Mcdermott JH, O'Driscoll L, Clynes M, Sreenan S. , Serum Messenger RNAs-Possible Biomarkers of Beta Cell Function in Diabetes Mellitus., Diabetes, American Diabetes Association , New Orleans, US, June 2009, 58, 2009, pp645 - 646 Published Abstract, 2009 URL

Kennedy SM, Tracey D, Doolan P, Mehta JP, Clynes M, O'Driscoll L. , Correlation of the Gene Expression Profile of Primary Breast Carcinoma with Clinical Outcome., Lab. Invest., 98th Annual Meeting of the United States and Canadian Academy of Pathology., Harvard, Boston, US., March 2009, 58, 2009, pp645 - 646 Conference Paper, 2009

Current Cancer Drug Targets, Bentham Science Publishers Ltd., 2009, - Critical Edition (Book), 2009 TARA - Full Text

Gene Expression Profiling, L O'Driscoll, 2nd Edition, New York:, Humana Press, 2009, 1 - 211 Critical Edition (Book), 2009 TARA - Full Text

Germano S, O'Driscoll L, Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to aid in Personalised Medicine, Curr Cancer Drug Targets, 9, (3), 2009, p398 - 418 Journal Article, 2009 URL DOI TARA - Full Text

Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R., Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines., Invest New Drugs, 28, (4), 2009, p433 - 444 Journal Article, 2009 TARA - Full Text DOI URL

Kennedy SM, Tracey D, Doolan P, Mehta JP, Clynes M, O'Driscoll L. , Correlation of the Gene Expression Profile of Primary Breast Carcinoma with Clinical Outcome., Modern Pathology, 22, 2009, pp50 - 50 Published Abstract, 2009

Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O Driscoll L., Expression of multidrug resistance markers ABCB1 (MDR-1/ Pgp) and ABCC1 (MRP-1) in renal cell carcinoma, BMC Urology, 24, (9), 2009, p6- Journal Article, 2009 URL TARA - Full Text DOI

O'Driscoll L, Doolan P, Clynes, M, 'Diagnostic, prognostic and/or predictive indicators of breast cancer', Publ.of the Int.Appl. without Int.search REP. - World Intellectual Property Organization, WO 2008132167 A3, 2009, 18 May 2009 Patent, 2009

P Doolan, M Clynes, S Kennedy, JP Mehta, S Germano, C Ehrhardt, J Crown, L O'Driscoll, TMEM25, REPS2 and Meis 1: Favourable prognostic and predictive biomarkers for breast cancer, Tumor Biol, 30, (4), 2009, p200-209 Journal Article, 2009 URL DOI

O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, Gammell P, Hill A, O'Daly B, O'Gorman D, Clynes M., Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR., Cancer Genomics Proteomics, 5, (2), 2008, p94 - 104 Journal Article, 2008 URL TARA - Full Text

Martinez V, Kennedy S, Doolan P, Gammell P, Joyce H, Kenny E, Prakash Mehta J, Ryan E, O'Connor R, Crown J, Clynes M, O'Driscoll L., Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue., Breast Cancer Res. Treat. , 110, (3), 2008, p521 - 530 Journal Article, 2008 DOI URL TARA - Full Text

Dowling P, Shields W, Rani S, Meleady P, Henry M, Jeppesen P, O'Driscoll L, Clynes M., Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction., Electrophoresis, 29, (20), 2008, p4141 - 4149 Journal Article, 2008 DOI URL TARA - Full Text

Hennessy E, O'Driscoll L., Molecular medicine of microRNAs: structure, function and implications for diabetes., Expert Rev Mol Med. , 10, 2008, p1 - 20 Journal Article, 2008 URL TARA - Full Text DOI

Germano S, Clynes M, Kennedy S, Mehta JP, Kenny E, Ryan E, Doolan P, Gaminell P, Joyce H, Perez de Villarreall M, Hill A, O'Daly B, Linehan R, Cronin D, Daly C, Glynn S, O'Driscoll L., Novel role of neuronal Calcium Sensor-1 (NCS-1) as Prognostic Factor and Therapeutic Target in Breast Cance. , Anticancer Res., 28, (5), 2008, pp3290 - 3291 Published Abstract, 2008

Kennedy S, Clynes M, Doolan P, Mehta JP, Rani S, Crown J, O'Driscoll L., SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue., Brit. J. Cancer, 98, (10), 2008, p1641 - 1645 Journal Article, 2008 DOI URL TARA - Full Text

Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M., Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines., Eur. J. Cancer, 44, (1), 2008, p151 - 159 Journal Article, 2008 TARA - Full Text DOI URL

Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L., Prevalence and prognostic and predictive relevance of PRAME in breast cancer, Breast Cancer Res. Treat. , 109, (2), 2008, p359 - 365 Journal Article, 2008 DOI TARA - Full Text URL

O'Driscoll L., Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers., Anticancer Res., 27, (3), 2007, p1257 - 1265 Journal Article, 2007 TARA - Full Text URL

O'Driscoll L, O'Connor R, Clynes M.(ed.), Proceedings and abstracts of the International Conference on Global mRNA and Protein Analysis., Anticancer Res., 27, (3), t. Inst. Anticancer Res., 2007, 1-1235 p Proceedings of a Conference, 2007

Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, Ballot J, Moriarty M, Crown J, Clynes M., 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins., Electrophoresis, 28, (23), 2007, p4302 - 4310 Journal Article, 2007 URL DOI

Mc Kiernan E, Barron NW, O'Sullivan F, Barham P, Clynes M, O'Driscoll L., Detecting de novo insulin synthesis in embryonic stem cell-derived populations., Exp. Cell Res. , 313, (7), 2007, p1405 - 1414 Journal Article, 2007 URL DOI TARA - Full Text

O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J., A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer., Cancer Chemother Pharmacol. , 59, (1), 2007, p79 - 87 Journal Article, 2007 URL DOI TARA - Full Text

O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S., MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma., Anticancer Res., 27, 2007, p2115 - 2120 Journal Article, 2007 TARA - Full Text URL

McKiernan E, O'Driscoll L, Kasper M, Barron N, O'Sullivan F, Clynes M., Directed differentiation of mouse embryonic stem cells into pancreatic-like or neuronal- and glial-like phenotypes., Tissue Eng., 13, (10), 2007, p2419 - 2430 Journal Article, 2007 DOI URL

Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, Perez De Villarreal M, Crown J, O'Driscoll L., MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer., Anticancer Res., 27, 2007, p1325 - 1330 Journal Article, 2007 URL TARA - Full Text

O'Driscoll, L., O'Connor, R., Clynes, M., Anticancer Research: Preface, Anticancer Research, 27, (3 A), 2007 Journal Article, 2007

Mehta JP, O'Driscoll L, Barron N, Clynes M, Doolan P., A microarray approach to translational medicine in breast cancer: how representative are cell line models of clinical conditions?, Anticancer Res., 27, 2007, p1295 - 1300 Journal Article, 2007 TARA - Full Text URL

O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L., Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents., Expert Opin Drug Metab Toxicol. , 3, (6), 2007, p805 - 817 Journal Article, 2007 TARA - Full Text URL DOI

Rani S, Clynes M, O'Driscoll L., Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function., Clin. Chem., 53, (11), 2007, p1936 - 1944 Journal Article, 2007 URL TARA - Full Text DOI

Dowling P, O'Driscoll L, O'Sullivan F, Dowd A, Henry M, Jeppesen PB, Meleady P, Clynes M., Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress., Proteomics, 6, (24), 2006, p6578 - 6587 Journal Article, 2006 TARA - Full Text DOI URL

O'Driscoll L, Clynes M., Molecular markers of multiple drug resistance in breast cancer., Chemotherapy, 52(3):125-9, (3), 2006, p125 - 129 Journal Article, 2006 TARA - Full Text DOI URL

Conway CM, O'Shea D, O'Brien S, Lawler DK, Dodrill GD, O'Grady A, Barrett H, Gulmann C, O'Driscoll L et al., The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line., BMC Bioinformatics, 17, (7), 2006, p256 - 268 Journal Article, 2006 URL TARA - Full Text DOI

O'Driscoll L., The emerging world of microRNAs., Anticancer Res., 26 , 2006, p4271 - 4278 Journal Article, 2006 URL TARA - Full Text

Keenan J, Pearson D, O'Driscoll L, Gammell P, Clynes M., Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture., Cytotech., 51, (1), 2006, p29 - 37 Journal Article, 2006 TARA - Full Text URL DOI

Walsh N, Kennedy S, Larkin A, Roy S, Ooi W, Gullo G, Ballot J, Clynes M, Crown J, O'Driscoll L , MDR1/P-Glycoprotein and MRP-1 Protein Expression in Pancreatic (CaP) & Non-Small Cell Lung Cancers (NSCLC). , Ann. Oncol., 17, (9), 2006, p64 - 65 Journal Article, 2006

Breen L, O'Driscoll L, Clynes M. , Gene Expression Microarray Technology: Some Applications in Lung Cancer Research., Cancer Genomics Proteomics, 3, (3-4), 2006, p197 - 202 Journal Article, 2006 TARA - Full Text

Setting up a Cell Culture Laboratory in, editor(s)Julio E. Celis , Cell Biology: A Laboratory Handbook. 3rd Edition , Oxford, UK, Elsevier Academic Press, 2006, pp5 - 12, [O'Connor R, O'Driscoll L. ] Book Chapter, 2006 DOI URL TARA - Full Text

O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M., Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays., Mol. Cancer, 5, 2006, p74 - 86 Journal Article, 2006 URL DOI TARA - Full Text

O'Driscoll L, Clynes M., Biomarkers and multiple drug resistance in breast cancer., Curr. Cancer Drug Targets , 6, (5), 2006, p365 - 384 Journal Article, 2006 URL TARA - Full Text DOI

Methods in Apoptosis in, Cell Biology: A Laboratory Handbook, International, Elsevier Academic Press, 2006, pp355 - 344, [O'Driscoll L, O'Connor R, Clynes M ] Book Chapter, 2006 URL TARA - Full Text DOI

O'Driscoll L, Gammell P, McKiernan E, Ryan E, Jeppesen PB, Rani S, Clynes M., Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells., J. Endocrinol. , 191, (3), 2006, p665 - 676 Journal Article, 2006 DOI TARA - Full Text URL

O'Driscoll L, Kenny E, Perez de Villarreal M, Clynes M, Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. , Cancer Genomics & Proteomics , 2, (1), 2005, p43 - 52 Journal Article, 2005 URL TARA - Full Text

O'Driscoll L, Gammell P, Clynes M., Expression in murine teratocarcinoma F9 cells of transcription factors involved in pancreas development., Transplant Proc. , 36, (4), 2004, p1511 - 1518 Journal Article, 2004 URL TARA - Full Text DOI

Liang Y, O'Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O'Connor R, Clynes M., Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs., Int. J. Cancer, 111, (4), 2004, p484 - 493 Journal Article, 2004 URL TARA - Full Text DOI

Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M., Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study., Int. J. Cancer, 112, (2), 2004, p286 - 294 Journal Article, 2004 URL DOI

O'Driscoll L, Gammell P, Clynes M., Mechanisms associated with loss of glucose responsiveness in beta cells., Transplant Proc. , 36, (4), 2004, p1159 - 1162 Journal Article, 2004 DOI URL TARA - Full Text

O'Driscoll, L., O'Connor, R., Clynes, M., "Biotechnology, cancer and drug resistance: New targets, new diagnosis and new treatment for tumours resistant to current therapies". Preface, Anticancer Research, 24, (2 A), 2004 Journal Article, 2004

O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M., Expression and prognostic relevance of Mcl-1 in breast cancer., Anticancer Res., 24, (2), 2004, p473 - 482 Journal Article, 2004 URL TARA - Full Text

Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M., Prognostic importance of survivin in breast cancer., Br J. Cancer, 88, (7), 2003, p1077 - 1083 Journal Article, 2003 TARA - Full Text URL DOI

Gammell P, O'Driscoll L, Clynes M., Characterisation of BHK-21 cells engineered to secrete human insulin, Cytotechnol., 41, (1), 2003, p11 - 21 Journal Article, 2003 URL TARA - Full Text DOI

O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, Glynn S, W McDermott E, D Hill A, J O'Higgins N, Parkinson M, Clynes M., Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer., Cancer Lett., 201, (2), 2003, p225 - 236 Journal Article, 2003 URL TARA - Full Text DOI

O'Driscoll L, Linehan R, Clynes M., Survivin: role in normal cells and in pathological conditions., Curr. Cancer Drug Targets , 3, (2), 2003, p131 - 152 Journal Article, 2003 URL TARA - Full Text DOI

Clynes M, O'Connor R, O'Driscoll L, Daly C, Meleady P., Challenges in molecular analysis for individualized cancer therapy., Drug Discov. Today, 8, (12), 2003, p531 - 533 Journal Article, 2003 DOI URL TARA - Full Text

O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I, Clynes M., Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro., Anticancer Res., 22, (6), 2002, p3117 - 3125 Journal Article, 2002 URL TARA - Full Text

O'Driscoll L, Gammell P, Clynes M., Engineering Vero cells to secrete human insulin, In Vitro Cell Dev. Biol. Anim. , 38, (3), 2002, p146 - 153 Journal Article, 2002 TARA - Full Text DOI URL

Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM., Matrix metalloproteinase expression and production by alveolar macrophages in emphysema., Am. J. Respir. Crit. Care Med., 156, (1), 1997, p240 - 247 Journal Article, 1997 TARA - Full Text DOI URL

Heenan M, O'Driscoll L, Cleary I, Connolly L, Clynes M., Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance., Int. J. Cancer, 71, (5), 1997, p907 - 915 Journal Article, 1997 TARA - Full Text URL DOI

Daly C, Coyle S, McBride S, O'Driscoll L, Daly N, Scanlon K, Clynes M., mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines., Cytotechnol., 19, (3), 1996, p199 - 205 Journal Article, 1996 TARA - Full Text URL

O'Driscoll LR, Finlay GA, Fitzgerald MX, O'Connor CM., Matrixmetalloproteinases expression by alveolar macrophages in emphysema, Thorax, 51, (3), 1996, p1 - 2 Journal Article, 1996 URL

O'Driscoll L, Kennedy S, McDermott E, Kelehan P, Clynes M., Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue., Eur. J. Cancer, 32, (1), 1996, p128 - 133 Journal Article, 1996 URL TARA - Full Text

Clynes M, Heenan M, McBride S, Cleary I, O'Driscoll L, Moran E. , Multiple drug resistance in variants of a human lung cell line exposed to adriamycin and VP-16. , J. Exp. & Clin. Cancer Res. , 14, 1995, p15 - 18 Journal Article, 1995 TARA - Full Text

O'Driscoll L, Daly C, Saleh M, Clynes M., The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells., Cytotechnol., 12, (1-3), 1993, p289 - 314 Journal Article, 1993 URL TARA - Full Text

Non-Peer-Reviewed Publications

Lowry MC, Breslin S, O'Driscoll, Investigating the role of CSF-1 and CAIX in neratinib-resistant HER2+ breast cancer cell lines and extracellular vesicles, International Society for Extracellular Vesicles (ISEV) 2018, Barcelona, Spain, 2-6 May, 2018 Oral Presentation, 2018

O'Driscoll L., Interview by HBM-LS (Lonza), 2018, - Miscellaneous, 2018 URL

O'Driscoll L, Keynotes Speaker: Exosomes and Ectosomes - friends & foes in cancer?, Dublin City University Research Day, Dublin City University, 26 January, 2018 Invited Talk, 2018

O'Driscoll L, Training in Extracellular Vesicles: for benefit in Health & Disease, International Society for Extracellular Vesicles (ISEV) 2018, Barcelona, Spain, 3 May, 2018 Invited Talk, 2018

Lowry MC, Breslin S, Conlon NT, Collins D, Eustace A, Crown J, Maher S, O'Sullivan J, O'Driscoll L, Investigating the role of CAIX in the mechanism of HER2-targeted drug resistance in breast cancer cells and extracellular vesicles , Breast-Predict showcase, UCD, Dublin, 17 October, 2018 Oral Presentation, 2018

O'Driscoll L, Characterisation and analysis of exosomes/extracellular vesicles, American Physiological Society: President's Symposium Series, San Diego, US, 22 April, 2018 Invited Talk, 2018

EU Commission/H2020, 'European Network on Microvesicles and Exosomes in Health & Disease', https://youtu.be/TmQBS5rPyEY, 2018, - Broadcast, 2018 Other

O'Driscoll L, Exosomes and Ectosomes: important Players in the Liquid Biopsy, Inaugural Cancer Research Club, University College Dublin, 21 November, 2017 Invited Talk, 2017

O'Driscoll L, Exosomes and Ectosomes in Breast (and other) Cancers, 10th International Symposium on Translational Research in Oncology, Herbert Park Hotel, Dublin, 27-29 September, 2017 Invited Talk, 2017

Lowry MC, Breslin S, Toomey S, Hennessy BT, O'Driscoll L, Investigation of mechanisms of neratinib-resistance in HER2-overexpressing Breast Cancer, Irish Association of Cancer Research Annual Meeting 2017, Newpark Hotel, Kilkenny, 22-24 February, 2017 Poster, 2017

O'Driscoll L, HER2-targeted drug resistance is associated with immune evasion in cancer cells and their derived EVs, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017 Oral Presentation, 2017

O'Driscoll L, Exosomes and Microvesicles: our Friends or Foes in Cancer?, European Research Night, Trinity Biomedical Sciences Institute, TCD, 28 September, 2017 Invited Talk, 2017

Lowry MC, Breslin S, Toomey S, Hennessy BT, O'Driscoll L, Investigating the mechanism of neratinib-resistance in HER2-overexpressing breast cancer, Irish Association of Pharmacologist Annual Conference 2017, Royal College of Surgeons in Ireland, Dublin, 30 November, 2017 Oral Presentation, 2017

O'Driscoll L, Microvesicles and Exosomes in Health and Disease, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017 Invited Talk, 2017

O'Driscoll L, Extracellular Vesicles (EVs) and Therapy, 24th Meeting of the EAU Section of Urological Research (ESUR), Institut Curie, Paris, France, 13 October, 2017 Invited Talk, 2017

Lowry MC, Breslin S, Toomey S, Hennessy BT, O'Driscoll L, Insights into the mechanisms of neratinib-resistance: investigating a possible role for EVs in HER2-overexpressing breast cancer, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017 Oral Presentation, 2017

O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L, Extracellular vesicles, extracellular vesicles-contained miRNAs and total miRNAs as plasma-based biomarkers for metabolic syndrome, International Society for Extracellular Vesicles (ISEV) 2016, Rotterdam, The Netherlands, 5 May, 2016 Oral Presentation, 2016

O'Driscoll L, Keynotes Speaker: Innovations in Cancer Research, CIBIO, Trento, Italy, February, 2016 Invited Talk, 2016

RTE, 'RTE Six-One and Nine o'clock news', 2016, - Broadcast, 2016

O'Driscoll L, Extracellular Vesicles: Biological & Therapeutic Potential, Extracellular Vesicles 2016, University of Cambridge, UK, 12 July, 2016 Invited Talk, 2016

O'Driscoll L, Cancer Research: the Future is Now, Five Year Celebration of Trinity Biomedical Sciences Institute, TBSI, TCD, 5 September, 2016 Invited Talk, 2016

O'Driscoll L, Keynotes Speaker: Extracellualr Vesicles in Breast Cancer - kill the messenger?, Microvesicles and Exosomes in Health and Disease, University of Ioannina, Greece, 4 March, 2016 Invited Talk, 2016

O'Driscoll L, The influence of Exosomes and Ectosomes in Cancer, Hypoxia and Angiogenesis, Weatherall Institute of Molecular Medicine, University of Oxford, UK, June, 2016 Invited Talk, 2016

O'Driscoll L, MEET-THE-EXPERT: Extracellular Vesicle as Modulators of Drug Resistance and Tumor Metastasis, 5th International Meeting of the International Society for Extracellular Vesicles (ISEV), De Deolen, Rotterdam Conference Centre, the Netherlands, 3 May, 2016 Invited Talk, 2016

Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, Extracellular Vesicle studies identify the potential diagnostic relevance of miR-134 as a biomarker for triple negative breast cancer and as a potential therapeutic option, 10th International Cancer Conference, Trinity Biomedical Sciences Institute, TCD, 18 October, 2016 Oral Presentation, 2016

Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in breast cancer-derived extracellular vesicles: potential biomarker and therapeutic option, Faculty of Health Sciences Research Day, Trinity Biomedical Sciences Institute, TCD, 15 September, 2016 Poster, 2016

Springer London(ed.), Royal Academy of Medicine in Ireland, Irish Journal of Medical Science, Brookfield Health Sciences Complex, Univeristy College Cork, 185, (Suppl. 1), 20/06/2013, Springer London Ltd, 236 Gray's Inn Road, London, 2016, S21 p Proceedings of a Conference, 2016

Daly M, O'Driscoll L, Investigating potential alternatives to "gold standard" ultracentrifugation for exosomes isolation, European network on microvesicles and exosomes in health and disease (ME-HaD) training course "Extracellular Vesicles & Exosomes: Analysis and Properties", University of Ioannina, Greece, 2 March, 2016 Oral Presentation, 2016

Daly M, O'Driscoll L, Investigating potential alternatives to "gold standard" ultracentrifugation for exosomes isolation, Irish Association for Cancer Research (IACR) Annual Meeting, Kingsley Hotel, Cork, 26 February, 2016 Poster, 2016

O'Driscoll L, 3D Cell Cultures in Drug Discovery, 18th International Pharmaceutical Technology Symposium, Hacettepe University, Ankara, Turkey, September, 2016 Invited Talk, 2016

Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity, Breast-Predict Midway Point Showcase, University College Dublin, 31 March, 2016 Oral Presentation, 2016

Daly M, O'Driscoll L, Circulating Exosomes: is there a high-throughput method comparable to the gold-standard ultracentrifugation for their isolation?, 38th All Ireland Schools of Pharmacy Research Conference, Royal College of Surgeons in Ireland, Dublin, 21 March, 2016 Poster, 2016

Lowry M, O'Driscoll L, Extracellular vesicle studies identify miR-134 as a potential biomarker and novel therapeutic target for breast cancer, Irish Association of Cancer Research Annual Meeting 2016, Kingsley Hotel, Cork, 26 February, 2016 Poster, 2016

Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in Breast Cancer-derived Extracellular Vesicles,  Irish Association of Pharmacologists (IAP) conference 2016, Royal College of Surgeons in Ireland, Dublin, 30 November, 2016 Oral Presentation, 2016

Daly M, O'Driscoll L, Comparison of high-throughput methods for extracellular vesicle isolation to "gold standard" ultracentrifugation, Faculty of Health Sciences Research Day, Trinity Biomedical Sciences Institute, TCD, 15 September, 2016 Poster, 2016

O'Driscoll L, What we can learning from studying Extracellular Signals in Cancer, Extracellular Vesicles in Health & Disease Meeting, University of Helsinki, Finland, 08 April, 2015 Invited Talk, 2015

O'Driscoll L, Exosomes and Ectosomes: our friends or foes in cancer?, Tumour Liquid Biopsy Symposium, Universitatsklinikum Freiburg, Germany, 29 October, 2015 Invited Talk, 2015

O'Driscoll L, Keynotes Speaker: Exosomes and Ectosomes in the Sub-types of Breast Cancer, Exosomes and Ectosomes in Health & Disease, Porto University, Portugal, 28 September, 2015 Invited Talk, 2015

Daly M, O'Driscoll L, Potential alternatives to gold standard ultracentrifugation for extracellular vesicle isolation, UK Extracellular Vesicles Forum, Cardiff University, UK, 15 December, 2015 Poster, 2015

Breslin S, Daly M, O'Donovan N, Crown J, O'Driscoll L, The potential of Neuromedin U as a biomarker in HER2-overexpressing breast cancer, Irish Association of Cancer Research Annual Meeting 2015, Castletroy Park Hotel, Limerick, 26 February, 2015 Poster, 2015

O'Driscoll L, MEET-THE-EXPERT: Exosomes as Diagnostics and Prognostics (Clinical importance of exosomes and microvesicles research in Europe), International Society for Extracellular Vesicles (ISEV) 2015, Washington DC, US, 26 April, 2015 Invited Talk, 2015

O'Driscoll L, Exosomes, their miRNAs and Cancer, MicroRNAs & Genome Editing, Cambridge University, UK, 2 November, 2015 Invited Talk, 2015

Breslin S, O'Driscoll L, Potential use of extracellular vesicles as diagnostic or predictive biomarkers for breast cancer, Eu COST BM1202 Microvesicles and Exosomes in Health and Disease (MEHAD), Helsinki, Finland, 2015 Oral Presentation, 2015

O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L, Circulating miRNA biomarkers for metabolic syndrome and obesity and their link with triple negative breast cancer, All Ireland Schools of Pharmacy Conference, Queen's University Belfast, 30 March, 2015 Oral Presentation, 2015

Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity, UK Extracellular Vesicles Forum, Cardiff University, UK, 15 December, 2015 Poster, 2015

O'Neill S, Bohl M, Hokamp K, Gregersen S, Hermansen K, O'Driscoll L, Circulating miRNAs: potential biomarkers for metabolic syndrome, All Ireland Schools of Pharmacy Conference, TCD, 14 April, 2014 Oral Presentation, 2014

O'Driscoll L, European Consortium on Microvesicles and exosomes in Health and Disease, Annual EU FP7 Co-operation Science & Technology Chairs Conference, Malta, 29 April, 2014 Invited Talk, 2014

Breslin S, O'Driscoll L, Investigating the role of neuronal calcium sensor-1 in acquired HER2 drug-resistance, 9th International Cancer Conference, Trinity Biomedical Sciences Institute, TCD, 18 September, 2014 Poster, 2014

O'Neill S, O'Driscoll L, Metabolic Syndrome & Cancer, 36th National Pharmacy Conference, Hamilton Building, TCD, 14 April, 2014 Oral Presentation, 2014

O'Neill S, Bohl M, Hokamp K, Gregersen S, Hermansen K, O'Driscoll L, Potential miRNA biomarkers for metabolic syndrome, RAMI Annual meeting 2014, University College Dublin, 19 June, 2014 Oral Presentation, 2014

O'Driscoll L, miR-134 transported in extracellular vesicles reduces triple-negative breast cancer aggression, International Society for Extracellular Vesicles (ISEV) 2014, De Deolen, Rotterdam Conference Centre, the Netherlands, 1 May, 2014 Oral Presentation, 2014

O'Neill S, Bohl M, Hokamp K, Gregersen S, Hermansen K, O'Driscoll L, Circulating miRNAs in Metabolic Syndrome and the Effect of Dietary Intervention on these miRNAs, Young Life Scientists Ireland (YLSI) Conference 2014, Trinity Biomedical Sciences Institute, TCD, 1 March, 2014 Poster, 2014

Rani S, O'Driscoll L, NCS-1 and acquired drug resistance in HER2-overexpressing breast cancer cells, 36th National Pharmacy Conference, Hamilton Building, TCD, 14 April, 2014 Oral Presentation, 2014

O'Driscoll L, Targeted Therapies for Breast cancer: the Highs and Lows beyond their Discovery, 9th International Cancer Conference, Trinity Biomedical Sciences Institute, TCD, 17 September, 2014 Invited Talk, 2014

O'Driscoll L, The relevance of exosomes in breast cancer , Microvesicles & Exosomes in Health and Disease, Univ. of Palermo, Sicily, Italy, 27 September, 2014 Invited Talk, 2014

Breslin S, O'Driscoll L, The effects of acquired neratinib-resistance on HER2-overexpressing breast cancer cells, TBSI Annual Symposium, Trinity Biomedical Sciences Institute, TCD, 9 May, 2014 Oral Presentation, 2014

O'Driscoll L, Identification of Circulating Nucleic Acids in Metabolic Syndrome, Annual DairyHealth Meeting, Aalborg, Sweden, 2 April, 2014 Invited Talk, 2014

Breslin S, Corcoran C, Rani S, O'Driscoll L, Acquired neratinib-resistance in breast cancer cells induces cross-resistance to HER-targeting drugs through a mechanism mediated by Hsp90, IGF1R, Bcl2 and caspase-8, Irish Association for Cancer Research (IACR) Annual Conference, Galway, 27 February, 2014 Poster, 2014

Dr. Claire O'Connell (author/Science Correspondent) writing about Prof. O'Driscoll's research, Cancer signals in the blood, 2013, - Miscellaneous, 2013

O'Driscoll L, Exosomes as Diagnostics and Predictive Biomarkers in Cancer, Biomarkers & Diagnostics World Congress, Philadelphia, US, May, 2013 Invited Talk, 2013

Corcoran C, O'Brien K, O'Driscoll L, MicroRNAs as Biomarkers & Therapeutics Targets for Cancer, Dublin microRNA Day, O'Callaghan Stephen's Green Hotel, Dublin, 29 May, 2013 Oral Presentation, 2013

Rani S, Germano S, Kennedy S, Crown J, O'Driscoll L, Clinical significance and functional relevance of melanoma-associated antigen family protein-D4 (MAGED-4) in breast cancer, European Discover Research Night, Dublin, 27 September, 2013 Oral Presentation, 2013

Rani S, O'Brien K, O'Donovan N, Crown J, O'Driscoll L, Role of exosome in acquired resistance to HER-targeted therapies in breast cancer, Microvesicles and Exosomes in Health and Disease, Herbert Park Hotel Dublin, 17 May, 2013 Oral Presentation, 2013

O'Driscoll L, Role of Exosomes in cancer cell communication, dissemination and resistance to therapy, "X European Society for Human Genetics Annual Conference, Paris, France, June, 2013 Invited Talk, 2013

Tormey WP (ed.)(ed.), Royal Academy of Medicines Ireland, Irish Journal of Medical Science, University College Cork, Ireland, 185, June 2013, 2013, 32-33 p Proceedings of a Conference, 2013

Breslin S, O'Driscoll L, Investigating the development of neratinib-resistance in HER2-overexpressing breast cancer cells, All Ireland Schools of Pharmacy Conference, Queen's University Belfast, 2013 Oral Presentation, 2013

O'Brien K, O'Driscoll L, Exosomal miRNAs in triple-negative breast cancer progression and treatment, Dublin microRNA Day, Dublin, 2013 Oral Presentation, 2013

O'Brien K, O'Driscoll L, Harnessing exosomes/microvesicles as microRNA therapeutic delivery vesicles in triple-negative breast cancer, European network on microvesicles and exosomes in health and disease (ME-HAD) inaugural meeting, Trinity College Dublin, 2013 Oral Presentation, 2013

O'Brien K, O'Driscoll L, Exosomes in TNBC, Triple negative breast cancer meeting, St. Vincent's University Hospital, 2013 Oral Presentation, 2013

O'Driscoll L, Metabolic Syndrome and Cancer, "X Metabolic Syndrome and Cancer Workshop, Skagen, Denmark, June, 2013 Invited Talk, 2013

O'Driscoll L, Extracellular Vesicles in Triple-Negative Breast Cancer, Institut Curie, INSERM U932, Paris, France, 28 July, 2013 Invited Talk, 2013

O'Brien K, O'Driscoll L, The Relevance of Exosomal-miRNAs in Triple-negative Breast Cancer Progression, International Society for Extracellular Vesicles annual scientific meeting, Boston, MA, US, 2013 Poster, 2013

Corcoran C, Rani S, Breslin S, Ghobrial IM, Crown J, O'Driscoll L, The potential of miR-630 , an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs, American Society for Clinical Oncology Annual Meeting, Chicago, Illinois, US, 31 May-4 June, 2013 Poster, 2013

Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L, Effects of acquired neratinib-resistance in breast cancer cell line variants, IACR, Dublin, 27 February-1 March, 2013 Poster, 2013

O'Brien K, O'Driscoll L, Exosomal miRNAs: potential communicators in triple-negative breast cancer, Irish Association for Cancer Research Annual Meeting, Dublin, 2013 Oral Presentation, 2013

Rani S, O'Brien K, O'Donovan N, Crown J, O'Driscoll L, Exosome-mediated response to HER-targeted therapies in breast cancer, IACR, Dublin, 27 February-1 March, 2013 Oral Presentation, 2013

Breslin S, O'Driscoll L, Investigating the effects and putative mechanism of acquired resistance to neratinib in breast cancer, Annual meeting of the Biomedical Sciences section of RAMI, 2013 Oral Presentation, 2013

O'Brien K, O'Driscoll L, Functional characterisation, profiling and therapeutic manipulation of breast cancer derived exosomes, Research seminar, Institut Curie, Paris, 2013 Oral Presentation, 2013

O'Brien K, O'Driscoll L, Exosomal miRNAs in triple-negative breast cancer, All Ireland Schools of Pharmacy Conference, University of Ulster, Belfast, 2013 Oral Presentation, 2013

Springer London(ed.), Royal Academy of Medicine in Ireland, Irish Journal of Medical Science, Brookfield Health Sciences Complex, Univeristy College Cork, 185, (Suppl. 1), 20/06/2013, Springer London Ltd, 236 Gray's Inn Road, London, 2013, S32-33 p Proceedings of a Conference, 2013

O'Brien K, O'Driscoll L, Can Exosomes influence Triple-negative breast cancer metastasis?, International Society for Extracellular Vesicles (ISEV) 2012, Gothenburg, Sweden, 2012 Poster, 2012

O'Brien K, O'Driscoll L, Assessing the influence of exosomes in triple-negative breast cancer, Irish Association for Cancer Research Annual Meeting, Belfast, 2012 Oral Presentation, 2012

Corcoran C, Rani S, O'Brien A, O'Neill A, O'Brien K, Prencipe M, Crown J, Watson W, O'Driscoll L, The relevance of exosome secretion in prostate cancer and their potential to confer docetaxel-resistance to secondary cells, 103rd Annual Meeting of the American Association for Cancer Research, Chicago, Illinois, US, 31 March-4 April, 2012 Poster, 2012

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Watson W, Crown J, O'Driscoll L, Exosomes - potential regulators and biomarkers of prostate cancer progression, International Society for Extracellular Vesicles (ISEV) 2012, Gothenburg, Sweden, 18-21 April, 2012 Poster, 2012

Rani S, O'Driscoll L, Neuromedin U: a novel target to overcome resistance to HER-targeted therapies and a potential predictive biomarker, TBSI Research Day, Trinity Biomedical Sciences Institute, TCD, 18 September, 2012 Oral Presentation, 2012

Rani S, Germano S, Madden S, Corcoran C, Breslin S, O'Brien N, McDermott M, Browne B, O'Donovan N, Crown J, O'Driscoll L, Neuromedin U: a potential predictive biomarker for HER2-targeted drugs, American Society for Clinical oncology (ASCO) Annual Meeting, Chicago, US, 1-5 June, 2012 Poster, 2012

O'Driscoll L, Our Quest for Tumour Biomarkers and New Therapeutic Targets , University of Colorado School of Pharmacy Seminar Series, April, 2012 Invited Talk, 2012

Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, McDermott R, Watson W, Crown J, O'Driscoll L, Prostate cancer progression: Do Exosomes play a role?, All Ireland Schools of Pharmacy Conference 2012, University College Cork, 1-2 April, 2012 Poster, 2012

O'Brien K, O'Driscoll L, The relevance of triple-negative breast cancer-derived exosomes in the transfer of aggressive phenotypic characteristics, All Ireland Schools of Pharmacy Conference, University College Cork, 2012 Oral Presentation, 2012

Corcoran C, Rani S, O'Brien A, O'Neill A, O'Brien K, Prencipe M, Crown J, Watson W, O'Driscoll L, Exosomes - potential mediators of prostate cancer progression?, Irish Association for Cancer Research Annual Meeting, Culloden Hotel, Belfast, 29 February-2 March, 2012 Oral Presentation, 2012

Rani S, Germano S, Madden S, Corcoran C, Breslin S, O'Donovan N, Crown J, O'Driscoll L, Neuromedin U expression is associated with resistance to HER2-targeted therapies and poor prognosis in breast cancer patients, Irish Association for Cancer Research Annual (IACR) meeting, Culloden Hotel, Belfast, 29 February-2 March, 2012 Poster, 2012

O'Driscoll L, KEYNOTES TALK: Cancer: the eXosome factor, "X International conference on Exosomes & Biomarkers in Cancer, University of Colorado at Denver, US, April, 2012 Invited Talk, 2012

Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L, Generation and characterisation of neratinib-resistant breast cancer cell line variants, EORTC-NCI-AACR Symposium, Dublin, 2012 Poster, 2012

Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L, Better ways of assessing anti-cancer drugs in the laboratory to increase their success for breast cancer patients, All Ireland Schools of Pharmacy Conference, University College Cork, 2012 Poster, 2012

O'Brien K, O'Driscoll L, Can triple-negative breast cancer cells transfer aggressive phenotypic characteristics via exosomes?, Scientific advisory board review of MTCI, Dublin, 2012 Oral Presentation, 2012

Corcoran C, Rani S, Browne B, Crown J, O'Donovan N, O'Driscoll L, Extracellular miRNAs have potential as minimally-invasive biomarkers for predicting response to HER2-targeted agents, including Trastuzumab, as used in breast cancer, 102nd Amer. Assoc. for Cancer Res. (AACR) annual meeting, Orlando, Florida, US, 2-6 April, 2011 Poster, 2011

Corcoran C, Rani S, O'Brien K, O'Neill A, Watson W, O'Driscoll L, Investigating the mechanisms of Docetaxel-resistance in prostate cancer, All Ireland Schools of Pharmacy Conference 2011, Royal College of Surgeons, Dublin, 18-19 April, 2011 Oral Presentation, 2011

Corcoran S, Rani S, O'Brien K, O'Neill A, Watson W, Crown J, O'Driscoll L. , The use of in vitro cell line models to investigate docetaxel-resistance in prostate cancer., Ir. J. Med. Sci. , 2011, 180, 2011, pp287 - 288 Published Abstract, 2011

Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L, Investigating clinical and functional relevance of MAGE-D4B in Breast cancer, Royal Academy of Medicine in Ireland and Biomedical Sciences Annual Meeting, Royal College of Surgeons in Ireland, Dublin [Awarded Barcroft Medal], 22 June, 2011 Oral Presentation, 2011

Corcoran C, Rani S, O'Brien K, Crown J, O'Driscoll L, Establishing and Characterising New in Vitro models of Docetaxel-resistance in Prostate Cancer, The European Multidisciplinary Cancer Congress, Stockholm, Sweden, 23-27 September, 2011 Poster, 2011

Rani S, Gately K, O'Byrne K, O'Driscoll L, Circulating miRNA as minimally-invasive biomarkers for adenocarcinoma of the Lung, 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July, 2011 Poster, 2011

Corcoran C, Rani S, Browne B, Crown J, O'Donovan N, O'Driscoll L. , The pursuit of miRNAs as minimally-invasive biomarkers predictive of response to anticancer treatment for HER2-positive breast cancer., J Pharm. Pharmaceut. Sci., 14, (3), 2011, pp205 - 218 Published Abstract, 2011

Rani S, O'Brien K, Friel A, Kelleher FC, Crown J, O'Driscoll L, Investigating the potential of circulating exosomes and their miRNA contents as minimally-invasive biomarkers for triple negative breast cancer, Irish Association for Cancer Research, Cork, 2-4 March, 2011 Poster, 2011

Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. , Investigating clinical and functional relevance of MAGE-D4B in breast cancer. , Ir. J. Med. Sci. , 180, 2011, pp295- Published Abstract, 2011

Rani S, O'Brien K, Friel A, O'Driscoll L, Exosomal miRNA as circulating biomarker in Triple Negative Breast Cancer, Breakthrough Triple Negative Breast Cancer, London, 9-11 March, 2011 Poster, 2011

Rani S, Gately K, O'Byrne K, O'Driscoll L, The relevance of circulating miRNAs as minimally-invasive biomarkers for non-small cell lung cancer, Pharmacy Conference, Dublin, University College Dublin, 2011 Poster, 2011

Barry S, Rani S, O'Driscoll L, Investigating acquired resistance to targeted anti-cancer agents in breast cancer, 2nd Year Medicine Research Poster Symposium, Department of Pharmacology and Therapeutics, Trinity College Dublin, 2011 Poster, 2011

Rani S, O'Brien K, McDonnell S, Hughes L, Friel AM, Radomski MW, Crown J, L O'Driscoll, Triple-negative breast cancer cells can transfer phenotypic characteristics via exosomes, The European Multidisciplinary Cancer Congress (ESMO), Stockholm, Sweden, 23-27 September, 2011 Poster, 2011

Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. , Investigating MAGE-D4B function in tumorigenesis and its potential as therapeutic target in breast cancer. , J Pharm. Pharmaceut. Sci. , Pharmacy Conference, Dublin, 14, (3), 2011, pp205 - 2018 Published Abstract, 2011

O'Brien K, O'Driscoll L, Triple-negative breast cancer cells can transfer phenotypic characteristics via exosomes, Exosomes and Microvesicles, Orlando, Florida, US, 2011 Oral Presentation, 2011

O'Brien K, Rani S, McDonnell S, Hughes L, Radomski MW, O'Driscoll L, Investigating naturally-occurring circulating nano-sized exosomes in cancer, All Ireland Schols of Pharmacy Conference, Royal College of Surgeons, Dublin, 2011 Oral Presentation, 2011

O'Brien K, Rani S, Friel AM, Kelleher FC, Crown J, Radomski MW, O'Driscoll L, Circulating exosomes in triple negative breast cancer: are these treasure chests of minimally-invasive biomarkers?, All Ireland Schools of Pharmacy Conference, Royal College of Surgeons, Dublin, 2011 Poster, 2011

Germano S, Rani S, O'Driscoll L, Melanoma-associated antigen family protein-D4B (MAGE-D4B) as a novel prognostic biomarker and therapeutic target for breast cancer, Advances in Cancer Research: From the Laboratory to the Clinic, Jordan, 7-10 March, 2010 Poster, 2010

Germano S, Rani S, Kennedy S, Crown J, Clynes M, O'Driscoll L, Melanoma-associated antigen family protein-D4 (MAGED-4): clinical significance and functional relevance in breast cancer, Breast Cancer Research, London, UK, 18 May, 2010 Poster, 2010

Germano S, Rani S, Kennedy S, Clynes M, Crown J, O'Driscoll L, Clinical significance and functional relevance of MAGED-4B in breast cancer, 35th ESMO Congress, Milan, Italy, October, 2010 Poster, 2010

Rani S, Mehta JP, Doolan P, Barron N, Jeppesen PB, Clynes M, O'Driscoll L, Txnip-identified as a regulator of glucose-stimulated insulin secretion and reactive oxygen species in MIN6 cells, "Translational Research": Applying molecular insights from laboratory discovery to clinical care, Ireland, 23-24 June, 2010 Oral Presentation, 2010

O'Driscoll L, The many forms of & many treatments for Breast Cancer, Cancer Awareness, 20 January, 2010 Invited Talk, 2010

Rani S, Mehta JP, Barron N, Doolan P, Clynes M, Jeppessen PB, O'Driscoll L., TXNIP-identified as a regulator of glucose-stimulated insulin secretion and reactive oxygen species in MIN6 cells., Ir. J. Med. Sci. , 179, (7), 2010, pp290 - 291 Published Abstract, 2010

Rani S, Germano S, Kennedy S, Clynes M, Crown J, O'Driscoll L, MAGE-D4B in Breast Cancer: assessment of Intracellular & Extracellular relevance, MTCI Breast Cancer Symposium, Dublin, November, 2010 Oral Presentation, 2010

O'Driscoll L, RNAs and Exosomes as Biomarkers and Potential Therapeutic Targets for Breast Cancer, 3rd World Breast Cancer Congress, Shanghai, China, 25 April, 2010 Invited Talk, 2010

Corcoran C, Rani S, Browne B, Crown J, O'Donovan N, O'Driscoll L, Identification of intracellular and extracellular miRNAs in SKBR3 and its Herceptin-resistant variant with potential as predictive biomarkers for breast cancer, EMBO|EMBL Symposium: Non-Coding Genome, October, 2010 Poster, 2010

O'Driscoll L, Intracellular & Extracellular Biomarkers associated with Breast Cancer, Frye Halloran Symposium, Harvard University, US, 5 November, 2009 Invited Talk, 2009

O'Driscoll L, Expression microarray analysis in human cancer., Anticancer Res., 27, (3), 2007, pp1371 - 1372 Published Abstract, 2007

Oglesby I, Clynes M, O'Driscoll L., Optimisation of siRNA transfection and its use in characterising the role of novel targets in a range of human carcinoma cell lines., Anticancer Res., 27, (3), 2007, pp1384 - 1385 Published Abstract, 2007

Coakley, R., O'Neill, S., Coakley, R., Glynn, P., O'Neill, S., Finlay, G.A., Russell, K.J., McMahon, K., D'Arcy, E.M., Masterson, J.B., Fitzgerald, M.X., O'Connor, C.M., O'Driscoll, L.R., Finlay, G.A., Fitzgerald, M.X., O'Connor, C.M., McGarvey, L.P.A., Forsythe, P., Heaney, L.G., MacMahon, J., Ennis, M., Leonard, C., Tormey, V., Burke, C.M., Poulter, L.W., Keatings, V.M., FitzGerald, M.X., Barnes, P.J., Harty, H.R., Corfield, D.R., Adams, L., Schwartzstein, R.M., Kiely, J.F., Buckley, A., Shiels, P., Deegan, P.C., Maurer, B., McNicholas, W.T., Dunlop, K.A., Martin, B., Riley, M., Shields, M.D., Glynn, P., Kilgallen, I., Coakley, R., O'Neill, S., McElvaney, N.G., Cervantes-Laurean, D., Wehr, N., Gabriele, K., Robinson, W., Moss, J., Levine, R.L., Urbach, V., Walsh, D., Harvey, B., McElroy, M.C., Pittet, J.-F., Allen, L., Wiener-Kroonish, J., Dobbs, L.G., O'Donnell, D.M., McMahon, K.J., O'Connor, C., Fitzgerald, M.X., McGuirk, P., Mahon, B., Griffin, F., Mills, K.H.G., Murphy, R., Brijker, F., Mulloy, E., Cohen Tervaert, J.W., Walshe, J., O'Neill, S., McGarvey, L.P.A., Heaney, L.G., Lowry, R.C., Shepherd, D.R.T., MacMahon, J., Gamble, L.A., Carton, C., Memon, R., Winter, D., Chan, A., Aherne, T., O'Reilly, P., Harbison, J.A., McNicholas, W.T., O'Callaghan, S., Mulloy, E., Keane, M., McKenna, M., Woods, S., O'Neill, S., Lamon, A., Leonard, C., Faul, J., Murphy, M., Burke, C.M., Tormey, V., Riley, M., Porszasz, J., Engelen, M.P.K.J., Brundage, B., Wasserman, K., Sweeney, M., O'Regan, R.G., McLoughlin, P., Sweeney, M., Honner, V., Sinnott, B., O'Regan, R.G., McLoughlin, P., Kilgallen, I., O'Neill, S., McGrath, D.S., Kiely, J., Cryan, B., Bredin, C.P., McGrath, D.S., Shortt, C., Stack, M., Kelleher, N., Bredin, C.P., Russell, K.J., McRedmond, J., Mulkerji, N., Keatings, V., Fitzgerald, M.X., O'Connor, C.M., Boylan, G.M., McElroy, M.C., Dobbs, L.G., Forsythe, P., McGarvey, L.P.A., Cross, L.J.M., Ennis, M., Heaney, L.G., MacMahon, J., Davern, S., O'Connor, C.M., McDonnell, T.J., Kiely, J.L., Lawless, G., Cunningham, S., McNicholas, W.T., Lordan, J., Clancy, L., Manning, P., Plunkett, P., Donaghy, D., Kiely, J., McDonnell, T.J., Ben Musbah, F., Loftus, B.G., Ben Musbah, F., Loftus, B.G., Rutherford, R., Watson, S.N.E., Gilmartin, J.J., Henry, M., Mullins, G., Brennan, N., Kiely, J.L., Deegan, P.C., McNicholas, W.T., Irish Thoracic Society - Proceeds of Annual Scientific meeting, November, 1996, Irish Journal of Medical Science, 167, (9 Supplement), 1998, p1-13 Journal Article, 1998

Research Expertise

Description

Bi-directional translational research; cancer research; diagnostic biomarkers; prognostic biomarkers; predictive markers; novel therapeutic targets; targeted therapies; pipeline drugs; monoclonal antibodies; small molecules; clinical and industry collaborations; breast cancer; lung cancer; prostate cancer; melanoma; multiple myeloma; circulating tumour cells (CTCs); multi-drug resistance; stem cells; differentiation; diabetes; islet transplants; microarrays; proteomics; mRNAs; microRNAs (miRNAs); clinical trials

Projects

  • Title
    • Extracellular Vesicles Promoted Regenerative Osseointegration (EVPRO)
  • Summary
    • This project, as part of the consortium programme entitled "Extracellular Vesicles Promoted Regenerative Osseointegration (EVPRO)" is a collaboration with the Fraunhofer, Aachen, Germany and 9 other European academic, clinical and industry partners that will develop EV-loaded hydrogel coatings with immunomodulatory activity for promoted regenerative osseointegration of revision endoprosthesis. The focus in the O'Driscoll group is on developing and optimising a down-stream process to isolate EVs released from mesenchymal stem cells (MSC-EVs), evaluating potency assays to assess the anti-inflammatory / immunomodulatory capacities of obtained MSC-EVs to modulate endoprosthesis induces inflammation processes, elucidating the molecule contents of MSC-EVs with the intention of identifying those that may be contributing beneficial effects, and transferring the MSC-EVs production process to GMP compliant conditions.
  • Funding Agency
    • EU Commission - Horizon 2020 (H2020)
  • Date From
    • Jan. 2019
  • Date To
    • Feb. 2023
  • Title
    • Extracellular vesicles: training in extracellular vesicles for benefit in health and disease (TRAIN-EV)
  • Summary
    • Exosomes and microvesicles/ectosomes, collectively termed extracellular vesicles (EV), have attracted much recent interest because of their potential functions, use as disease biomarkers and possible therapeutic exploitation. Due to their enormous relevance, this relatively new field of research is quickly expanding. However, there are still many gaps in knowledge that need to be addressed to ensure optimal exploitation of EVs from health and Europe's economic benefit. Addressing this, TRAIN-EV's objective is to provide excellent and integrated multi-disciplinary and inter-sectoral training of a critical mass of ESRs of outstanding potential in the academic, clinical, and industry/business components of exploiting EV, while performing novel cutting-edge research to address these gaps and generate new knowledge. This will be achieved by appointing 15 PhD students with Beneficiary and Partner Organisations offering secondments, training and additional networking opportunities. --- €3,900,500
  • Funding Agency
    • EU Commission - Horizon 2020 (H2020)
  • Date From
    • 2017
  • Date To
    • 2021
  • Title
    • Milking extracellular vesicles for improved infant milk formula (MilkEV)
  • Summary
    • My research group has found human breast milk and cows milk contain tiny sacs called EVs. Their studies suggest EVs would not be destroyed in the gut and may be absorbed into the bloodstream. When infants suckle, EVs are believed to help build up their immune system. MilkEV's first objective is to investigate differences between human and cows milk EVs and see if any EV loses during infant milk formula (IMF) manufacture can be prevented or restored. The second objective is to further evaluate milk EVs as protective "delivery vehicles" for oral administration. The intended benefits include helping to design best possible IMF. This is of societal importance and of economic relevance too, given that ~10% of the world's IMF is manufactured in Ireland. MilkEV should also help progress towards delivery of beneficial substances (e.g. biotherapeutics) that would otherwise be destroyed in the gut (€595,014).
  • Funding Agency
    • Dept. of Agriculture, Food and Marine (DAFM)
  • Date From
    • July 2018
  • Date To
    • June 2022
  • Title
    • Exosomal Neuromedin U and miR-X: potential predictive biomarkers for HER2-targeted drugs
  • Summary
    • A new range of anti-cancer drugs have become available that are used to treatment some breast cancer patients. The best known one is Herceptin (trastuzumab), but there are other new drugs in this family. These drugs were designed to interact with HER2, a molecule found at greater amounts on cancer cells compared to normal cells for ~25% of breast cancer patients. These drugs are more cancer-specific than older chemotherapy and can offer advantages of greatly helping many patients without causing serious side-effects. Unfortunately, some patients who seem suitable candidates based on the HER2 test, don't benefit from these treatments. Some others respond at first, but then become unresponsive (resistant) to the treatment. Added to the problem of some patients not benefiting, these drugs are extraordinarily expensive costs to healthcare. We urgently need ways of predicting which patients with "HER2 tumours" are likely to benefit. We also need to be able to overcome the resistance problem. Studying cells from breast tumours, we recently found two molecules, NmU and miR-X, at substantially different amounts both inside and outside cells that are resistant to these drugs compared to those that are sensitive. By "tweaking" their amounts in the cells, we can make cells more resistant or more sensitive to these drug; suggesting that this approach might help overcome the serious resistance problem in tumours. So, (i) we explained this study to many patients enrolling in clinical trials using these drugs. They donated blood specimens that we want to test to see if analyse for NmU and miR-X can predict those who will/won't respond; (ii) we are at a stage where we now need to progress our work of "tweaking" NmU and miR-X to see if we can help overcome this resistance in a living organism.
  • Funding Agency
    • Health Research Board
  • Date From
    • Feb. 2014
  • Date To
    • Feb. 2017
  • Title
    • European Network on Microvesicles & Exosomes in Health and Disease
  • Summary
    • Microvesicles and Exosomes (ME) have attracted much recent interest because of their potential functions, use as disease biomarkers and possible therapeutic exploitation. Due to their enormous relevance, through nationally-funded projects throughout Europe, this relatively new field of research is quickly expanding. There are, however, many associated issues that need to be addressed to ensure optimal research performance and collation and cross-interpretation of data. These issues range from the need to derive a consensus on fundamental guidelines/nomenclature and optimal techniques for vesicle isolation and analysis, to more advanced issues such as collating emerging data and expertise towards better understanding, and thus exploiting, the physiological and pathological roles of ME. There is also urgency to identify gaps in ME knowledge and how best collaborative research can address these questions. This Consrtium creates a network of European experts, fostering a multidisciplinary approach to enhance both basic understanding and translational potential of ME.
  • Funding Agency
    • EU H2020
  • Date From
    • Jan 2013
  • Date To
    • Dec 2018
  • Title
    • Breast-PREDICT
  • Summary
    • Breast-PREDICT is a country-wide collaboration between experts in the area of breast cancer research, funded by the Irish Cancer Society. This 'virtual Centre' was launched in October 2013 and will run for a period of five years. Breast-PREDICT brings together researchers from six academic institutions across Ireland: UCD, TCD, RCSI, DCU, NUIG and UCC, and a nationwide clinical trials group, ICORG. We collect information and tumour samples from nearly every breast cancer patient in the country, with their consent. Using these valuable resources, we will improve our understanding of how this disease can spread and become resistant to treatment, and find ways to combat this with new and better therapies. This is a multi-disciplinary Centre, which unites breast cancer experts with different skills, to work towards a common goal.
  • Funding Agency
    • Irish Cancer Society
  • Date From
    • Nov. 2013
  • Date To
    • Oct. 2018
  • Title
    • Biomarkers & Therapeutics Targets: MeS, Diabetes and Cancer
  • Summary
    • In vitro, in vivo and clinical trials studies including researchers from ireland, Denmark, The Netherlands, and Germany to identify and validate biomarkers & new therapeutics targets of potential relevant to metabolic syndrome, diabetes and cancer
  • Funding Agency
    • Danish Strategic Research Council / EU
  • Date From
    • March 2013
  • Date To
    • Feb. 2016
  • Title
    • Exploring the Relevance of Exosomes in Cancer
  • Funding Agency
    • IRCSET
  • Date From
    • Oct 2011
  • Date To
    • Sept 2014
  • Title
    • Marie Keating Foundation PhD Scholarship at Trinity College Dublin
  • Summary
    • Better ways of assessing anti-cancer drugs in the laboratory to increase their success for breast cancer patients
  • Funding Agency
    • Marie Keating Foundation, Trinity Foundation, TCD
  • Date From
    • April 2011
  • Date To
    • March 2015
  • Title
    • Marie Keating Foundation PhD Scholarship at Trinity College Dublin
  • Summary
    • Developing blood tests for earlier diagnosis & optimal treatment selection for breast cancer patients
  • Funding Agency
    • Marie Keating Foundation, Trinity Foundation, TCD
  • Date From
    • Jan 2010
  • Date To
    • Jan 2015
  • Title
    • Molecular Therapeutics for Cancer
  • Summary
    • This Cluster of scientific, clinical, industrial partners, with support from the All Ireland Clinical Oncology Research Group (ICORG) focusses on Molecular Therapeutics for Cancer. This fully-integrated translational cancer drug discovery and development programme will significantly benefit cancer patients. Our industry patners include SRC's Industry Partners are GlaxoSmithKline, Pfizer, Merck Sharpe & Dohme, Novartis, Roche, and Amgen. SFIs support for this SRC is €7.3m.
  • Funding Agency
    • Science Foundation Ireland (SFI)
  • Date From
    • Oct 2009
  • Date To
    • Sept 2014
  • Title
    • New Diagnostic and Prognostic Biomarkers for Age-Related Macular Degeneration
  • Funding Agency
    • IRCSET
  • Date From
    • Oct 2010
  • Date To
    • Sept 2013
  • Title
    • Characterisation of 2 Novel mRNAs Present in Breast Tumours - but not Normal Breast Tissue - with potential as Therapeutic Targets & Diagnostic/Prognostic Biomarkers.
  • Summary
    • We have identified, using whole genome expression microarray analysis of a large bank of breast cancer and normal breast biopsies, two novel poorly characterised transcripts which do not occur in normal breast but are found in more than one third of breast cancer biopsies. Kaplan-Meier, X2 and Cox Regression analyses showed that expression of each of these transcripts is significantly associated with poor prognosis. We propose to characterise and investigate the function of these two genes, which were not present in previously published microarray analyses, in order to assess their possible importance in breast cancer cell biology, as therapeutic targets and as diagnostic/prognostic/predictive markers. In this project, we propose to isolate and sequence the full length cDNAs, and to investigate homologies to better characterised genes with known roles within the cell. We will investigate the functions of these genes in relation to properties such as cell growth rate, cell survival, cell division, invasion, drug resistance and soft agar colony formation, in a panel of breast cancer cell lines using cDNA and SiRNA transfections. qRT-PCR will be used to choose cell lines most appropriate for up- or down-regulation of expression. Peptides from the predicted protein structure will be used to raise antibodies for Western Blotting and immunocytochemistry. GFP-tagged cDNAs will be prepared in order to investigate subcellular localisation of the gene products. By analogy with the her2/herceptin diagnostic/therapeutic pairing, we hope this project may lead to identification of new specific targets for diagnosis and therapy of subsets of breast carcinoma patients.
  • Funding Agency
    • Health Research Board
  • Date From
    • October 2006
  • Date To
    • March 2010
  • Title
    • Biomarkers (mRNAs, miRNAs, proteins) for Type 1 & Type 2 Diabetes
  • Summary
    • Type 2 diabetes mellitus (T2DM) is associated with reduced β-cell function, relatively reduced β-cell mass and insulin resistance. Serum biomarkers of β-cell mass and/or function have not been described. Amplifiable mRNAs, which have been detected in conditioned medium from cultures of insulin-producing animal cell-lines, if detectable in human serum, could serve as markers of β-cell mass. We attempted to detect these mRNAs in serum from patients with newly diagnosed T2DM and compared them to healthy controls. We recruited T2DM subjects (mean DM duration 4.36±2.33 months) and controls (age, gender and BMI matched). Medical history, physical exam and fasting bloods were obtained. Serum mRNA levels were analysed using real time quantitative reverse transcription-PCR. Two mRNAs, thioredoxin interacting protein (Txnip) and early growth response factor 1 (Egr1), previously associated with cell-line glucose responsiveness, were detected.Levels of Egr1 were lower and levels of Txnip tended to be higher in T2DM. Egr1 level correlated positively with smoking history in pack-years (ρ=0.485, p=0.042), total (ρ=0.554, p=0.017) and LDL cholesterol (ρ= 0.495, p= 0.043). Txnip level correlated positively with age (ρ= 0.471, p=0.042) and HOMA%S (ρ= 0.489, p= 0.034) but not with smoking history or cholesterol level. To our knowledge, this is a first description of detectable serum mRNAs possibly linked to the diagnosis of diabetes. Significance of this finding is unclear at present and confounding variables may have an effect on these results.
  • Funding Agency
    • Higher Education Authority & Seed Funding
  • Date From
    • Oct 2008
  • Date To
    • Jan 2011
  • Title
    • Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer
  • Summary
    • The standard of care for hormone refractory prostate cancer (HRPC) is taxotere (generally 2-3 weekly; for 10 cycles). This treatment increases overall survival (OS) by, on average, 2.5 months. Mechanisms are not currently available to determine (i) those patients who are most suitable/would benefit from this treatment; (ii) why this benefit is short-term (why relapse/resistance occurs); and (iii) which patients are unlikely to respond to taxanes and so should potentially be offered targeted therapies. The primary objective is to establish if gene expression in circulating tumour cells (CTC) from HRPCs patients is predictive of response to therapy.
  • Funding Agency
    • Adnagen
  • Date From
    • Jan 2008
  • Date To
    • Dec 2010
  • Title
    • Lungmark
  • Summary
    • Discovery & validation of panels of new diagnostic and theranostic blood-Based biomarkers for lung cancer
  • Funding Agency
    • Enterprise Ireland (under National Strategic Dev. Plan 2007-2013 co-financed by ERDF)
  • Date From
    • 5 Oct 2009
  • Date To
    • 31 March 2011
  • Title
    • 3D Printed Extracelluar Vesicles for in situ Bone Tissue Regeneration
  • Summary
    • Stem cell therapy can repair bone defects caused by trauma or resection of cancerous tumors. Stem cells secrete small packages called extracellular vesicles (EVs) which are thought to be involved in this healing. The objective of this innovative research is to develop implants comprised of EVs and biomaterials to heal bones. Cutting-edge technology will permit the fabrication of implants to exactly fit the shape of the patient's broken bones. Since this is a cell-free, off-the shelf therapy, it will reduce pain since it won't require a bone or bone marrow harvest, be less expensive, and available to more patients, compared to stem cell therapy.
  • Funding Agency
    • Science Foundation Ireland
  • Date From
    • Dec 2019
  • Date To
    • Nov 2023

Keywords

Apoptosis; Apoptosis, molecular control; Bioinformatics; Biology; Biology and therapy of myeloma; Biomedical sciences; Breast cancer; Cancer genetics and cell biology including metastasis; Cell and tissue development; Cell and tissue maintenance, repair and ageing; Clinical research, trials; Diabetes and diabetic complications; Diagnostics; DNA transcription and translation; Drug development and evaluation; Drug discovery, profiling, targeting; Embryonic development; Endocrine function and disease; Gene targeting in breast cancer; Gene therapy; Gene transcription in human cancer; Human genetics; Immunoassays; In vitro testing, trial methods; Medical Sciences, Research; Membrane and protein trafficking; Multiple Myeloma; Oncogenes, apoptosis and tumour development; Pathology; Prostate cancer; Regulatory methods of gene expression; RNA processing, stability and degradation; Stem Cell biology and hematopoiesis; Therapeutic and Clinical oncology

Recognition

Representations

Chair, Career Development Sub-Committee, FHS Athena Swan Application 2018

Founding Director, TRAIN-EV training in extracellular vesicles: for benefit in health and disease. 2017

Invited Role Model, Inspiring Leadership - Leadership Foundation for Higher Education (Aurora), Ireland and UK 2016

Management Committee member, H2020-funded cooperation in science and technology: Delivery of Antisense RNA Therapeutics 2018

Editorial Board Member for Encyclopaedia of Bioscience Frontier in Bioscience 2007

Management Committee member, H2020-funded cooperation in science and technology: Identifying Biomarkers through Translational Research for Prevention and Stratifictaion of Cancer 2018

Secretary to Science and Meetings Committee, ISEV 2018

Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling - 2nd Edition 2018

Editorial Board Member for Cancer Genomics & Proteomics 2006

Editorial Board Member, Anticancer Research 2009

Editorial Board Member, J. Extracell. Ves. 2013

Editorial Board Member, PeerJ 2012

Guest-Editor of book volume of Current Cancer Drug Targets entitled "Mechanisms of Cancer Drug Sensitivity & Resistance: A Translational Approach" 2009

Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling 2009

Research Specialist: All Ireland Clinical Oncology Research Group/Cancer Trials Ireland (& Principal Investigator on Phase I & II cancer clinical trials) 2005

Appointed as Strand Leader, Irish Cancer Society (ICS)-funded national virtual research centre Breast-Predict 2013

Cancer Theme Steering Committee member, Trinity College Dublin 2012

Management Committee member, Irish Cancer Society (ICS)-funded national virtual cancer research centre Breast-Predict 2013

Mentor, Career path Development, University College Los Angeles (UCLA) 2011

Management Committee member, Science Foundation Ireland-funded national virtual cancer research centre Molecular Therapeutics for Cancer Ireland 2009

Strategic Advisory Board Member, Midatech Ltd, Oxford 2014

Hospital Professional Awards: Judguing Panel Member 2014

External Examiner to Aarhus University postgraduate degree programmes 2010

External Examinder for 29 PhD candidates including studenst in: Oxford Univeristy, Cambridge University, Aarhus University, Edinburgh University, Cardiff University, University College London, Queen's University Belfast, Royal College of Surgeons of Ireland, National University of Ireland Galway, University College Dublin, Univeristy College Cork 2005

External Examiner/Panel Member to Athlone Institute of Technology for Higher Education and Training Awards Council (HETAC) 2006

Examiner (Report and Site Visit) for Enterprise Ireland Applied Research Capability award to Dundalk Institute of Technology 2013

Frequently review for journals incl. Oncogene, Eur. J. Cancer, J. Medical Virol., Tissue Eng., J. Histochem. Cytochem., Stem Cells, Anticancer Res., Exp. Opin. Drug Discovery, BMC Development Biology, Diabetes, Obesity & Metabolism, Cancer Detect. Prevent., The Review of Diabetes Studies, Cancer Genomics & Proteomics, Differentiation, FEBS Lett., Exp. Opin. Mol. Diag., Eur. J. Pharmaceutical Sci, Experimental Haematol., Personalized Medicine, Circulation Res., Biochemica Medica, Cancer, Eur. J. Pharmacol., Leukaemia Res., Biochem. Pharmacol., Exp. Opin. Therap. Targets, J. Pharmacy & Pharmacol., Brit. J. Dermatol., Clin. Chem., BBA Cancer, Cancer Res., Nature, Nature Medicine, The Lancet 2001

Editorial Board Member, Molecular Biotechnology 2010

Editorial Board Member, BMC Cancer å 2011

Editorial Board Member, Journal of Biomarkers 2012

Awards and Honours

Elected Fellow of Trinity College Dublin 2012

MA (jure oficii) 2012

Memberships

Elected Member of the Board of Directors, International Society for Extracellular Vesicles (ISEV) 2018

Founding Committee Member, Irish Association of Pharmacologists (IAP) 2016 – present

Founding Chair, European Network on Microvesicles and Exosomes in Health and Disease 2013 – present

Invited Member of Irish Cancer Society (ICS) Research Capacity Building Committee 2011 – 2013

Invited Member of the International Institute of Anticancer Research (IIAR) Scientific Advisory Board 2006 – present

Deputy-President of the Irish Branch of the European Tissue Culture Society (ETCS) 2005 – 2010

Director, Irish Association for Cancer Research (IACR) 2008 – 2014

Member of the European Association for Cancer Research (EACR) 2006 – present

Member of Irish Network of Stem-Cell Investigators (INNSI) 2004 – 2010

Board Member of the National Institute for Cellular Biotechnology 2002 – 2008

Member of the National Institute for Cellular Biotechnology Scientific Advisory Board 2002 – 2008

Elected Member on Dublin City University's Research Advisory Panel 2002 – 2008

Elected Member on Dublin City University's Faculty of Science & Health Research Committee 2003 – 2008

Member of British Pharmacological Society 2016 – present

Member, European Assoication for Cancer Research (EACR) 2008

Member, American Society for Cancer Research (AACR) 2007

Member, American Society for Clinical Oncology (ASCO) 2007

Member, European Society for Medical Oncology (ESMO) 2006